Evaluation of Sequential Urine Analysis when Selecting Candidates for Vesicoamniotic Shunting in Lower Urinary Tract Obstruction.


Journal

Fetal diagnosis and therapy
ISSN: 1421-9964
Titre abrégé: Fetal Diagn Ther
Pays: Switzerland
ID NLM: 9107463

Informations de publication

Date de publication:
2021
Historique:
received: 26 11 2020
accepted: 31 01 2021
pubmed: 24 3 2021
medline: 25 11 2021
entrez: 23 3 2021
Statut: ppublish

Résumé

The objective of our study was to assess the utility of sequential fetal urine analysis in severe lower urinary tract obstruction (LUTO) when selecting cases suitable for vesicoamniotic shunting. This was a retrospective cohort study of cases of severe LUTO treated in our fetal medicine center from 1994 to 2013. Two fetal bladder samples were taken 24-48 h apart to assess renal function. A vesicoamniotic shunt was inserted in case of improvement in urinary biochemistry between the 2 samples. We assessed perinatal morbidity and mortality and renal function at 5 years. Among a total of 26 LUTO cases with sequential urine analysis, 5 showed normal urinary biochemistry, 13 were abnormal, and 8 improved between the 2 samples. These 8 cases underwent vesicoamniotic shunt placement, leading to the birth of 6/8 (75%) live infants, 5/6 (83%) of whom had normal renal function at 5 years. The 5 cases with normal biochemistry occasioned 2 neonatal deaths and 3 children with normal renal function at 5 years. Elective termination of pregnancy was requested by parents for the fetuses exhibiting abnormal biochemistry. An improvement in urinary biochemistry between 2 sequential fetal bladder punctures in severe LUTO could be an effective criterion in the selection of candidates for vesicoamniotic shunting. However, the benefit of a shunt in fetuses with normal amniotic fluid remains to be evaluated in clinical trials.

Identifiants

pubmed: 33756463
pii: 000514911
doi: 10.1159/000514911
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

265-271

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Antoine Koch (A)

Maternal Fetal Medicine Department, Strasbourg University Hospital, Strasbourg, France, antoine.koch@chru-strasbourg.fr.

Romain Favre (R)

Maternal Fetal Medicine Department, Strasbourg University Hospital, Strasbourg, France.

Anne-Sophie Weingertner (AS)

Maternal Fetal Medicine Department, Strasbourg University Hospital, Strasbourg, France.

Ariane Zaloszyc (A)

Pediatric Nephrology Department, Strasbourg University Hospital, Strasbourg, France.

Monique Kohler (M)

Maternal Fetal Medicine Department, Strasbourg University Hospital, Strasbourg, France.

Fernando Guerra (F)

Maternal Fetal Medicine Department, Strasbourg University Hospital, Strasbourg, France.

Jonathan Rosenblatt (J)

Maternal Fetal Medicine Department, Robert Debré Hospital, AP-HP, Paris, France.

Françoise Muller (F)

Biochemistry-Hormonology Department, Robert Debré Hospital, AP-HP, Paris, France.

Sophie Dreux (S)

Biochemistry-Hormonology Department, Robert Debré Hospital, AP-HP, Paris, France.

Nicolas Sananès (N)

Maternal Fetal Medicine Department, Strasbourg University Hospital, Strasbourg, France.
INSERM, UMR-S 1121, "Biomatériaux et Bioingénierie", Strasbourg, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH